# An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria

> **NCT02515279** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 463 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02515279
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 463 (ACTUAL)
- **Last updated:** 2017-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02515279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02515279, "An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT02515279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*